In the past week, REGN stock has gone down by -7.17%, with a monthly decline of -1.64% and a quarterly plunge of -24.15%. The volatility ratio for the week is 4.28%, and the volatility levels for the last 30 days are 4.36% for Regeneron Pharmaceuticals, Inc The simple moving average for the last 20 days is -4.95% for REGN’s stock, with a simple moving average of -33.97% for the last 200 days.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Right Now?
The price-to-earnings ratio for Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is 13.94x, which is above its average ratio. Moreover, the 36-month beta value for REGN is 0.39. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for REGN is 104.06M and currently, short sellers hold a 2.50% of that float. On May 09, 2025, REGN’s average trading volume was 1.06M shares.
REGN) stock’s latest price update
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has experienced a decline in its stock price by -2.36 compared to its previous closing price of 560.93. However, the company has seen a fall of -7.17% in its stock price over the last five trading days. https://www.prnewswire.com reported 2025-05-02 that LOS ANGELES, May 2, 2025 /PRNewswire/ — Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots in biopharma, Landmark Science bridges the gap between vendors and biopharma, delivering agile and efficient solutions uniquely tailored to clients. This hand-held approach through and through helps clients avoid typical red tape situations that can delay or halt critical evidence generation to swiftly transform evidence into insights on patient care, access, and outcomes. Landmark Science founder and CEO, Shivani Aggarwal, PhD, MS, brings 15 years of experience in RWE and clinical trials from her time at leading life science companies Amgen, Regeneron, and IQVIA. With deep scientific acumen and a strong track record in evidence generation, Shivani Aggarwal drives Landmark Science’s strategic vision, spearheading the delivery of innovative, data-driven solutions to help patients. “Our approach goes beyond traditional evidence generation—we partner closely with our clients to provide tailored, high-touch support that meets their unique needs,” says Shivani Aggarwal. “By combining deep industry expertise with cutting-edge methodologies, we empower biopharma organizations with impactful insights that drive innovation and regulatory success at exceptional speed.” With a team of seasoned epidemiologists and advanced statistical programmers, Landmark Science offers bespoke solutions with a comprehensive suite of services, including data landscaping, full-scale RWE studies, and advanced analytics. Landmark Science brings unparalleled expertise to some of the most complex therapeutic areas and offers pan-therapeutic solutions to provide invaluable support across various disease areas including hematology, oncology, immunology, and rare disease. The company leverages its extensive experience to help clients successfully navigate the rapidly evolving RWE landscape. As the demand for high-quality, real-world evidence grows, Landmark Science stands at the forefront, ensuring its clients receive rigorous scientific insights and the highest personalized service. About Landmark Science, Inc. Landmark Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE in drug development. Landmark Science’s team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, and regulators and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit www.landmarkscience.com or contact [email protected]. Media Contact:Landmark Science[email protected]+1 (424) 535-3011https://landmarkscience.com/
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Cantor Fitzgerald repeating the rating for REGN by listing it as a “Overweight.” The predicted price for REGN in the upcoming period, according to Cantor Fitzgerald is $695 based on the research report published on April 22, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see REGN reach a price target of $834, previously predicting the price at $762. The rating they have provided for REGN stocks is “Outperform” according to the report published on February 05th, 2025.
UBS gave a rating of “Neutral” to REGN, setting the target price at $738 in the report published on January 16th of the current year.
REGN Trading at -12.21% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.78% of loss for the given period.
Volatility was left at 4.36%, however, over the last 30 days, the volatility rate increased by 4.28%, as shares sank -5.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.53% lower at present.
During the last 5 trading sessions, REGN fell by -7.17%, which changed the moving average for the period of 200-days by -48.80% in comparison to the 20-day moving average, which settled at $576.20. In addition, Regeneron Pharmaceuticals, Inc saw -23.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.85 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.32. The total capital return value is set at 0.11. Equity return is now at value 15.96, with 12.51 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 98.59.
Currently, EBITDA for the company is 5.32 billion with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 4.1. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To wrap up, the performance of Regeneron Pharmaceuticals, Inc (REGN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
